What is Svetlana Kolchinsky email address?

Svetlana Kolchinsky's primary email address is ********@catalystcr.com. To view the full verified email and additional contact details, sign up for free with Muraena.

What company does Svetlana Kolchinsky work for?

Svetlana Kolchinsky is a Vice President, Clinical Development Operations at Catalyst Clinical Research, a company specializing in Commercial physical research.

Where Svetlana Kolchinsky graduated from?

Svetlana Kolchinsky holds a degree in Biotechnology from Johns Hopkins University.

How can I directly contact Svetlana Kolchinsky?

To contact Svetlana Kolchinsky directly, you can use the email address ********@catalystcr.com. Complete contact information is available upon registration with Muraena.

Is Svetlana Kolchinsky an immigrant?

Yes, Svetlana Kolchinsky is an immigrant and currently based in United States

Who is Svetlana Kolchinsky?

Svetlana Kolchinsky is an accomplished Clinical Research Professional with over 15 years of extensive experience in Clinical Project Management and Leadership, particularly in the biopharmaceutical and biotechnology sectors. She has a strong background in all phases of clinical development, with a focus on Oncology projects, including Breast, Lung, and Head & Neck cancers. Svetlana's career began at NIH, where she explored the realms of neurology research before transitioning to clinical research at the Immune Tolerance Network. Her leadership roles at several prominent organizations, including Catalyst Clinical Research and Nanobiotix, highlight her ability to effectively manage complex projects and foster collaboration among cross-functional teams. Svetlana's passion for her work is evident in her commitment to supporting the development of life-changing medical therapies. Her educational credentials include multiple degrees from Johns Hopkins University, specializing in Biotechnology, underscoring her strong technical foundation in the field. As a dedicated professional, she continues to make significant contributions to clinical research and drug development.